# Clonal dissection of immunodominance and cross-reactivity of the CD4<sup>+</sup> T cell response to SARS-CoV-2

Jun Siong Low<sup>1†,</sup> Daniela Vaqueirinho<sup>1†</sup>, Federico Mele<sup>1†</sup>, Mathilde Foglierini<sup>1</sup>, Michela Perotti<sup>1</sup>, David Jarrossay<sup>1</sup>, Sandra Jovic<sup>1</sup>, Tatiana Terrot<sup>2</sup>, Alessandra Franzetti Pellanda<sup>3</sup>, Maira Biggiogero<sup>3</sup>, Christian Garzoni<sup>3</sup>, Paolo Ferrari<sup>4,5,6</sup>, Alessandro Ceschi<sup>2,4,7,8</sup>, Antonio Lanzavecchia<sup>9</sup>, Antonino Cassotta<sup>1,‡,\*</sup>, and Federica Sallusto<sup>1,10,‡,\*</sup>.

<sup>1</sup>Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.

<sup>2</sup>Trial Unit, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

<sup>3</sup>Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.

<sup>4</sup>Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.

<sup>5</sup>Department of Internal Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

<sup>6</sup>Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.

<sup>7</sup>Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.

<sup>8</sup>Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.

<sup>9</sup>National Institute of Molecular Genetics, 20122 Milano, Italy.

<sup>10</sup>Institute of Microbiology, ETH Zürich, Switzerland.

\* Corresponding authors: federica.sallusto@irb.usi.ch; antonino.cassotta@irb.usi.ch

<sup>†,‡</sup> Equal contribution

#### Abstract

The identification of CD4<sup>+</sup> T cell epitopes is essential for the design of effective vaccines capable of inducing neutralizing antibodies and long-term immunity. Here we demonstrate in COVID-19 patients a robust CD4<sup>+</sup> T cell response to naturally processed SARS-CoV-2 Spike and Nucleoprotein, including effector, helper and memory T cells. By characterizing 2,943 Spike-reactive T cell clones, we found that 34% of the clones and 93% of the patients recognized a conserved immunodominant region encompassing residues S346-365 in the RBD and comprising three nested HLA-DR and HLA-DP restricted epitopes. By using pre- and post-COVID-19 samples and Spike proteins from alpha and beta coronaviruses, we provide in vivo evidence of cross-reactive T cell responses targeting multiple sites in the SARS-CoV-2 Spike protein. The possibility of leveraging immunodominant and cross-reactive T helper epitopes is instrumental for vaccination strategies that can be rapidly adapted to counteract emerging SARS-CoV-2 variants.

The prompt identification of T cell epitopes in disease causing organisms is a considerable challenge in view of the polymorphism of HLA class II molecules and the variability of rapidly mutating pathogens. Bioinformatic analysis is widely used to predict peptide binding to HLA molecules and to identify candidate targets of the T cell response (1). In the context of the COVID-19 pandemic, this approach has been used to predict T cell epitopes in SARS-CoV-2 proteins (2, 3) and to produce peptide pools that have been used to stimulate PBMCs in order to identify and enumerate antigen-specific T cells. These studies revealed a robust CD4<sup>+</sup> and CD8<sup>+</sup> T cell response against SARS-CoV-2 Spike, Membrane, Nucleoprotein and non-structural proteins in recovered patients (2-6) and a level of cross-reactivity with other circulating human coronaviruses in prepandemic samples (7-9).

A limitation of bioinformatic-based predictions is the difficulty to identify immunodominant epitopes, since immunodominance depends on multiple factors such as the constraints related to processing of whole proteins, the available T cell repertoire, HLA alleles and preexisting cross-reactive immunity (*10-12*). To identify naturally processed immunodominant CD4<sup>+</sup> T cell epitopes we took an unbiased approach of stimulating memory CD4<sup>+</sup> T cells with protein-pulsed professional antigen presenting cells (APCs), followed by the isolation of T cell clones that were used to precisely map the epitope recognized (*13*). In addition, TCR V $\beta$  sequencing was used to define diversity and frequency of SARS-CoV-2-specific clonotypes within memory subsets and to estimate the extent of cross-reactivity with other coronavirus Spike proteins.

To analyze the CD4<sup>+</sup> T cell response elicited by SARS-CoV-2, we collected blood samples from patients who had recovered from mild to severe COVID-19 disease 43-164 days post symptoms onset or positive PCR test (Table S1). From PBMCs of a first cohort of 14 patients, we isolated total CD4<sup>+</sup> memory T cells or CD4<sup>+</sup> T central memory (Tcm), T effector memory (Tem) and T circulating follicular helper (cTfh) cells (Fig. S1A). The cells were labelled with CFSE and stimulated with autologous monocytes in the presence of recombinant SARS-CoV-2 Spike or Nucleoprotein. In all patients we observed a strong proliferative response towards both antigens, as measured on day 6 by CFSE dilution, upregulation of ICOS and CD25 and production of IFN- $\gamma$ , the latter being primarily detected in the Tcm and Tem subsets (**Fig. 1A, B** and **Fig. S1B, C**). The proliferative response was overall comparable in the three memory subsets, consistent with priming of both inflammatory Th1, helper T and memory T cells. In contrast, in unexposed individuals, the CD4<sup>+</sup> memory T cell response to SARS-CoV-2 proteins was low or undetectable (**Fig. 1B** and **Fig. S1C**), consistent with the presence of a few cross-reactive T cells primed by seasonal coronaviruses (*4, 5, 9*).

The clonal composition of SARS-CoV-2-reactive memory T cell lines and the relationship between different memory subsets was studied in three patients (P28, P31 and P33) by TCR V $\beta$  sequencing of Spike-stimulated and Nucleoprotein-stimulated CFSE<sup>lo</sup> T cell lines generated from each of the memory subsets. The Tcm, Tem and cTfh cell lines generated from the three patients comprised on average 908, 480 and 697 Spike-reactive clonotypes and 1,452, 623 and 908

Nucleoprotein-reactive clonotypes, respectively (**Fig. 1C** and **Fig. S2**). Interestingly, several of the most expanded clonotypes were shared between two and even among all three subsets, as shown by a high similarity index (**Fig. 1C, D**). Collectively, these findings reveal a robust polyclonal  $CD4^+$  T cell response to SARS-CoV-2 antigens. The polyfunctional response and the sharing of clonotypes among Tcm, Tem and cTfh cells is consistent with previous studies on the lineage relationship of CD4<sup>+</sup> T cell subsets and with the intraclonal diversification of antigen primed CD4<sup>+</sup> T cells (*14, 15*).

In view of the interest in vaccine design, we analyzed in depth the CD4<sup>+</sup> T cell response to the Spike protein and in particular to the RBD, which is the main target of neutralizing antibodies (*16*, *17*). CD4<sup>+</sup> memory T cells from a larger cohort of 34 COVID-19 recovered patients (**Table S1**) were stimulated with Spike protein-pulsed APCs and proliferating T cells were isolated by cell sorting and cloned by limiting dilution. Using this approach, we obtained 2,943 T cell clones and mapped their specificity using 3 pools of 15-mer peptides overlapping of 10 spanning the S1-325 and S536-685 sequences (pool S1<sub>ΔRBD</sub>, comprising 91 peptides), the S316-545 sequence (pool RBD, comprising 44 peptides) and the S676-1273 sequence (pool S2, comprising 118 peptides) (**Fig. 2A, B**). Most donors analyzed (32 out of 34) had T cell clones specific for the RBD region (**Fig. 2B**). Further experiments using recombinant RBD to stimulate CD4<sup>+</sup> memory T cells led to the isolation of additional clones from all patients tested, including P8 and P21. Collectively, these findings demonstrate that, in spite of its relatively small size, the RBD is recognized by CD4<sup>+</sup> T cells of all individuals tested and accounts on average for 20% of the CD4<sup>+</sup> T cell response to the Spike protein (**Fig. 2B**).

Using a matrix-based approach, we mapped the epitope specificity of 1,149 RBD-reactive CD4<sup>+</sup> T cell clones isolated from 30 patients (**Fig. 2C**). This analysis showed that in each patient T cell clones recognize multiple sites that altogether covered almost all the RBD sequence. Individual patterns were clearly evident, most likely reflecting restriction by different HLA class II molecules. However, certain regions emerged as immunodominant, such as those spanning residues S346-385 and S446-485 (**Fig. 2C**). Strikingly, a 20 amino acid region (S346-365) was recognized by 93% of the donors (28 out of 30) and by 34% of the clones (396 out of 1,149) (**Fig. 2D**). This region is highly conserved among human Sarbecoviruses, including the recently emerged variants of concern (VOC), and zoonotic Sarbecoviruses (**Fig. 2E**) (*18*). RBD-specific and S346-365-specific clones were found in the Tcm, Tem and cTfh subsets, consistent with priming of effector and memory T cells (**Fig. S3A, B**). Collectively, these findings demonstrate that RBD is highly immunogenic in vivo and identify a large number of naturally processed T cell epitopes including a conserved immunodominant region.

To dissect the CD4<sup>+</sup> T cell response to the immunodominant S346-365 region, we sequenced TCR V $\beta$  chains of 323 specific T cell clones. The 200 clonotypes identified used a broad spectrum of TCR V $\beta$  genes and, even in the same donor, carried different CDR3 sequences (**Fig. 3A, B** and **Table S2**). The TCR V $\beta$  sequences of T cell clones specific for the S346-365 region isolated from

patients P31 and P33 were also detected in the repertoire of total  $CD4^+$  memory T cells immediately after isolation from peripheral blood and some of them were among the top 5% clonotypes (**Fig. 3C**).

To determine the HLA class II isotype used by S346-365-specific T cell clones, we stimulated the clones in the presence of blocking antibodies to HLA-DR, -DP and -DQ (**Fig. 3D, E**). Most of the T cell clones analyzed (n = 240 from 20 patients) were HLA-DR-restricted, while the remaining (45 from 4 patients) were HLA-DP-restricted and one was HLA-DQ-restricted. The minimal peptide epitope recognized by HLA-DR- and HLA-DP-restricted T cell clones was mapped using a panel of truncated peptides (**Fig. 3F**). Interestingly, while HLA-DR-restricted clones from P31, P32 and P33 recognized the same 10 amino acid peptide (VYAWNRKRIS), HLA-DR-restricted clones from P29 recognized a different 12 amino acid peptide (RFASVYAWNRKR) and HLA-DP-restricted clones from P33 recognized an 11 amino acid peptide (NRKRISNCVAD). Collectively, these findings indicate that the S346-365 region comprises at least three nested epitopes recognized in association with different allelic forms of HLA-DR or HLA-DP by T cell clones that use a large set of TCR V $\beta$  genes and CDR3 of different sequence and length.

To address the extent of T cell cross-reactivity between different Spike proteins, SARS-CoV-2 Spike-specific T cell lines from patients P28 and P33 were re-labelled with CFSE and stimulated with autologous monocytes pulsed with Spike proteins from other beta (SARS-CoV, HKU1 and OC43) or alpha (NL63 and 229E) coronaviruses. In these patients, a robust proliferation of SARS-CoV-2-specific T cell lines in the secondary cultures was observed in response to SARS-CoV and HKU1 (**Fig. 4A**). TCR V $\beta$  sequencing of primary and secondary cultures identified a subset of cross-reactive clonotypes (**Fig. S4**). Out of 1,674 and 568 clonotypes present in the primary SARS-CoV-2-specific T cell lines from P28 and P33, 17% and 25% were found in SARS-CoV secondary cultures and 11% and 15% were found in HKU1 secondary cultures. Remarkably, 7% and 8% of the clonotypes were found in both SARS-CoV and HKU1 stimulated cultures suggesting the existence of T cell clones with broad specificity. To corroborate this finding, we isolated from secondary cultures several T cell clones that proliferated in response to 2 or even 3 different Spike proteins (**Fig. 4B** and **Table S3**). Importantly, the dose response curves indicate recognition of naturally processed peptides with similar functional avidity.

To ask whether cross-reactive T cells could be detected in pre-COVID-19 samples and could be expanded early on following SARS-CoV-2 infection, we analyzed the T cell response in a COVID-19 recovered patient from whom we had previously cryopreserved PBMCs. Memory CD4<sup>+</sup> T cells from pre- and post-COVID-19 samples were stimulated with a panel of recombinant Spike proteins (**Fig. 4C**). In this individual, a robust T cell proliferation in the pre-COVID-19 sample was detected primarily against alpha coronaviruses NL63 and 229E, while the response to beta coronaviruses HKU1 and OC43 was limited and the response to SARS-CoV and SARS-CoV-2 was undetectable. Conversely, in the post-COVID-19 sample a strong T cell proliferation was observed not only in response to SARS-CoV-2, but also in response to all other alpha and beta coronavirus Spike

proteins. This was accompanied by the appearance of antibodies against SARS-CoV-2 as well as an increase in serum antibody titers against HKU1 and OC43 (J.S.L., unpublished data).

The striking increase in the response to unrelated Spike proteins in the post-COVID-19 sample may be caused by the recall of pre-existing cross-reactive memory T cells or the priming of cross-reactive T cells. To measure the extent of cross-reactivity, we isolated T cell clones from SARS-CoV-2-, SARS-CoV-, OC43- or NL63-reactive memory T cell lines and found that a variable proportion of these clones proliferated in response to a SARS-CoV-2 Spike peptide pool (**Fig. 4D**). The specificity of cross-reactive T cell clones was further mapped using peptide pools to the different SARS-CoV-2 Spike domains and was found to be primarily directed against the S2 domain but to comprise also T cell clones reactive to the S1 or RBD domain (**Fig. 4E**). Collectively, these findings identify, at the clonal level, an extensive CD4<sup>+</sup> T cell cross-reactivity among coronavirus Spike proteins, which primarily targets the S2 domain, consistent with its higher degree of sequence identity (*19-21*).

Using naturally processed antigens for the isolation of almost 3,000 CD4<sup>+</sup> T cell clones, we unbiasedly mapped the T cell epitopes recognized by patients recovered from COVID-19. At variance with initial reports, we document a robust CD4<sup>+</sup> T cell response to the RBD and identified a conserved immunodominant region encompassing residues S346-365 in the RBD that is recognized by virtually all donors, a finding that is relevant for vaccine design since the RBD is also the target of most neutralizing antibodies (*16*, *17*). These findings were not anticipated in previous studies based on bioinformatics predictions (*2*, *3*) and short-term peptide stimulation of bulk PBMCs, highlighting the value and suitability of classical unbiased T cell stimulation and cloning approach for the dissection of antigen-specific T cell repertoires.

The reason for the immunodominance of RBD S346-365 may be due to the presence of at least three nested T cell epitopes presented by HLA-DR and HLA-DP as shown in this study, but may also be due to the relative abundance of naturally processed peptides, as previously observed in the context of the immunodominant response to influenza hemagglutinin (*13*). Indeed, peptides spanning the immunodominant regions here identified were also detected by HLA class II immunopeptidomics in dendritic cells pulsed with SARS-CoV-2 Spike protein (*22*). Interestingly, the immunodominant S346-365 region is conserved among different Sarbecoviruses and has not been found mutated in the new SARS-CoV-2 VOC isolates. Furthermore, this region is also a contact site for a broadly reactive neutralizing antibody (*23*), providing a striking example of convergence of T and B cells around a conserved epitope.

Sequencing of TCR V $\beta$  locus in T cell clones and polyclonal cultures reveals that SARS-CoV-2 infection primes a large CD4<sup>+</sup> T cell response comprising inflammatory and helper T cells, as well as precursors of long-lived memory T cells. In this primary response, it was interesting to find evidence for an extensive clonal diversification towards different fates and functions, as previously demonstrated in mice and in in vitro primed human naïve T cells (*14, 15*). Furthermore, the detection of a large repertoire of SARS-CoV-2 reactive cTfh cells is indicative of robust germinal

center reaction, which is necessary for the deployment of high affinity antibodies (24). Follow-up studies on clonotype dynamics and persistence will allow to dissect the development of T cell memory to a relevant pathogen and to test different models of memory generation (25).

Our results also highlight the extensive cross-reactivity of Spike-specific T cells that can be documented in vivo and not only between the closely related Sarbecoviruses (SARS-CoV-2 and SARS-CoV) but also with the more divergent endemic coronaviruses. The availability of a large number of cross-reactive T cell clones is not only instrumental to define target sites in relevant pathogens but also to understand whether cross-reactivity is due to epitope structural similarities or to TCR binding degeneracy (*11, 26*).

While the narrow specificity of neutralizing antibodies can readily select escape mutants, the extensive sequence coverage and breadth observed in the CD4<sup>+</sup> T cell response to SARS-CoV-2 Spike antigen offers an opportunity for vaccine design. The possibility of leveraging a robust cross-reactive T helper cell function against conserved sites will be instrumental to drive neutralizing antibody responses to adaptive vaccines that incorporate escape mutations found in emerging SARS-CoV-2 variants.

#### Materials and Methods

# Study subjects

Blood samples were obtained from a cohort of COVID-19 convalescent patients collected between June 8, 2020 and November 24, 2020 and from healthy donors collected and cryopreserved in summer 2019 (obtained from the Swiss Blood Donation Center of Basel and Lugano, prepandemic samples) or on November 2018 (P34). The study protocol was approved by the Cantonal Ethics Committee of Ticino, Switzerland (CE-TI-3428, 2018-02166). All blood donors provided written informed consent for participation in the study. Human primary cell protocols were approved by the Federal Office of Public Health (no. A000197/2 to F.S.). Illness of SAoV-2 infected CDC individuals was categorized according to the guidelines (https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/) as: i) asymptomatic if they tested positive for SARS-CoV-2 and reported any COVID-19-related symptoms; ii) mild if they reported any of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell, but no shortness of breath, dyspnea, or abnormal chest imaging; iii) moderate if evidence of lower respiratory disease during clinical assessment or imaging and with oxygen saturation (SpO2)  $\geq$ 94% on room air; iv) severe if SpO2 <94% on room air.

# Cell purification and sorting

Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque Plus (GE Healthcare) gradient. CD14<sup>+</sup> monocytes and total CD4<sup>+</sup> T cells were isolated by positive selection using CD14

and CD4 magnetic microbeads, respectively (Miltenyi Biotech). Total CD4<sup>+</sup> cells were stained at 37°C for 15 min with a primary anti-human-CXCR5 (clone 51505; cat. no. MAB190) from Bio-Techne, followed by staining with a biotinylated secondary goat anti-mouse IgG2b (cat. no. 1090-08) from Southern Biotech. After washing, cells were stained with PE/Cy7-Streptavidin (cat. no. 405206) from BioLegend, and with the following fluorochrome-labeled mouse monoclonal antibodies: CD8-PE-Cy5 (clone B9.11; cat. no. A07758), CD56-PE/Cy5 (clone N901; cat. no. A07789) from Beckman Coulter, CD25-PE (clone M-A251; cat. no. 555432) from BD Biosciences, CD4-PE–Texas Red (clone S3.5; cat. no. MHCD0417), CD45RA-Qdot 655 (clone MEM-56; cat. no. Q10069) from ThermoFisher Scientific, CCR7-BV421 (clone G043H7; cat. no. 353208) from BioLegend. Memory CD4<sup>+</sup> T cells were sorted to over 98% purity on a FACSAria III (BD) after exclusion of CD8<sup>+</sup>, CD56<sup>+</sup>, CD25<sup>br</sup> cells and CD45RA<sup>+</sup>CCR7<sup>+</sup>) naïve CD4<sup>+</sup> T cells. In some experiments, memory CD4<sup>+</sup> T cells were divided in cTfh (sorted as CXCR5<sup>+</sup> cells), Tcm (sorted as CCR7<sup>+</sup>CXCR5<sup>-</sup> cells) and Tem (sorted as CCR7<sup>-</sup>CXCR5<sup>-</sup> cells).

# Antigens and peptides

The following recombinant proteins were purchased from Sino Biological Inc: SARS-CoV-2 (2019-nCoV) Spike protein (S1+S2 ECD, cat.no. 40589-V08B1), SARS-CoV-2 (2019-nCoV) Nucleocapsid protein (cat.no. 40588-V08B), SARS-CoV (S577A, Isolate Tor2) Spike protein (S1+S2 ECD, cat.no. 40634-V08B), HCoV-HKU1 (isolate N5) Spike protein (S1+S2 ECD, cat.no. 40606-V08B). Peptides were synthesized as crude material on a small scale (1 mg) by Pepscan (Lelystad, The Netherlands). Peptides used in the study included 15mers overlapping of 10 covering the entire sequences of SARS-CoV-2 Spike protein (UniProtKB: P0DTC2; 253 peptides).

# Cell culture and T cell stimulation

T cells were cultured in RPMI 1640 medium supplemented with 2 mM glutamine, 1% (vol/vol) nonessential amino acids, 1% (vol/vol) sodium pyruvate, penicillin (50 U/ml), streptomycin (50  $\mu$ g/ml) (all from Invitrogen) and 5% human serum (Swiss Red Cross). Sorted memory CD4<sup>+</sup> T cells were labelled with 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE, ThermoFisher) and cultured at a ratio of 2:1 with irradiated autologous monocytes untreated or pulsed for 3 h with recombinant SARS-CoV-2 Spike protein (2.5  $\mu$ g/ml). After 6 days, cells were stained with antibodies to CD25-PE (clone M-A251; cat. no. 555432) from BD Biosciences and ICOS-APC (clone C398.4A; cat. no. 313510) from BioLegend. Cytokine concentrations in the day 6 supernatants of antigen-stimulated cultures were assessed by Luminex bead-based assay (Thermo Fisher Scientific) according to the manufacturer's instructions. Proliferating, activated T cells were FACS-sorted as CFSE<sup>10</sup>CD25<sup>+</sup>ICOS<sup>+</sup>, expanded in vitro in the presence of IL-2 (500 IU/ml) and cloned by limiting dilution. In some experiments, CFSE<sup>10</sup> cultures were relabeled with CFSE and re-stimulated with antigen-pulsed irradiated autologous monocytes; readout of T cell proliferation was determined at day 4-5 after secondary stimulation.

#### Isolation and characterization of T cell clones

T cell clones were isolated from CFSE-low cells by limiting dilution using 1 µg/mL PHA-P, 1000U/ml IL-2 and allogeneic irradiated PBMCs. T cell clone reactivity was determined by stimulation with a set of 253 synthetic peptides (15mers overlapping of 10) spanning SARS-CoV-2 Spike protein (1.5 µM per peptide) in the presence of irradiated autologous monocytes or EBVimmortalized B cells as APCs. To determine the SARS-CoV-2 Spike domains targeted by T cell clones, the set of 253 peptides was grouped in 3 different pools spanning the following amino acid ranges: S1-325 and S536-685 (pool S1ARBD, comprising 91 peptides); S316-545 (pool RBD, comprising 44 peptides); S676-1273 (pool S2, comprising 118 peptides). To determine the minimal sequence targeted by SARS-CoV-2 RBD-reactive T cell clones, the 44 peptides comprising the pool RBD were subdivided into 5 horizontal and 5 vertical peptide pools to construct a RBD epitope mapping matrix. Epitope mapping of SARS-CoV-2 RBD was performed by stimulation of T cell clones with irradiated autologous APCs, untreated or pre-pulsed with the RBD epitope mapping matrix (1.5 µM per peptide). Specificity to a region of 20 amino acids was assigned upon reactivity to one of the 5 horizontal and one of the 5 vertical pools. In some experiments, SARS-CoV-2 Spike peptides were titrated by serial dilution. To determine HLA restriction, T cell clones were stimulated with autologous APCs pulsed with SARS-CoV-2 Spike peptides, in the absence or presence of blocking anti-class II monoclonal antibodies produced in house from hybridoma cell lines (anti-HLA-DR, clone L243 from ATCC, cat. no. HB-55; anti-HLA-DQ, clone SPVL3 (27); anti-HLA-DP, clone B7/21 (28), anti-pan-MHC-class-II, clone IVA12 from ATCC, cat. no. HB-145). In all experiments proliferation was assessed on day 3, after incubation for 16 h with 1 µCi/ml [methyl-<sup>3</sup>H]-thymidine (Perkin Elmer). Data were expressed as counts per min (Cpm) or as  $\Delta$ cpm after subtraction of control cultures performed in the absence of antigen.

# Sequence analysis of TCR Vβ genes

Sequence analysis of rearranged TCR V $\beta$  genes of T cell clones was performed as previously described. Briefly, cDNA from individual T cell clones was obtained by reverse transcription of total RNA from 10<sup>3</sup>-10<sup>4</sup> cells per reaction. Rearranged TCR V $\beta$  genes were PCR amplified using forward primer pool targeting V $\beta$  genes, and reverse primer pairing to C1–C2  $\beta$ -chain constant region. Sequence amplification was assessed through agarose gel electrophoresis; successfully amplified fragments were sequenced by Sanger method, and TCR sequence annotation was carried out by using IMGT/V-QUEST algorithm (*29*).

# TCR Vβ deep sequencing

Ex vivo-sorted memory CD4<sup>+</sup> T cell subsets and CFSE<sup>10</sup> fractions of antigen-stimulated memory CD4<sup>+</sup> T cell cultures were analyzed by deep sequencing. In brief,  $5 \times 10^5$  T cells were centrifuged and washed in PBS and genomic DNA was extracted from the pellet using QIAamp DNA Micro Kit (Qiagen), according to manufacturer's instructions. Genomic DNA quantity and purity were assessed through spectrophotometric analysis. Sequencing of TCR V $\beta$  CDR3 was performed by

Adaptive Biotechnologies using the ImmunoSEQ assay (http://www.immunoseq.com). In brief, following multiplex PCR reaction designed to target any CDR3 V $\beta$  fragments; amplicons were sequenced using the Illumina HiSeq platform. Raw data consisting of all retrieved sequences of 87 nucleotides or corresponding amino acid sequences and containing the CDR3 region were exported and further processed. The assay was performed at deep level for ex vivo-sorted memory CD4<sup>+</sup> T cell subsets (detection sensitivity, 1 cell in 200,000) and at survey level for CFSE<sup>lo</sup> antigenreactive cultures (detection sensitivity, 1 cell in 40,000). Each TCR V $\beta$  clonotype was defined as the unique combination of a productively rearranged CDR3 amino acid sequence and its related V and J genes (bioidentity); data processing was done using the productive frequency of templates provided by ImmunoSEQ Analyzer V.3.0 (http://www.immunoseq.com). For each repertoire, a frequency corresponding to the top 5th percentile in the frequency-ranked list of unique clonotypes was chosen as threshold (top 5%). Chao-Jaccard overlap between pairs of TCR V $\beta$  repertoires was calculated using R package "fossil" (*30*).

#### Conservation analysis

Accession numbers of Spike protein sequences used for S346-365 conservation analysis are: SARS-CoV-2 Wuhan-Hu-1/2019 (GenBank: NC\_045512.2); SARS-CoV-2 B.1.1.7 (GISAID: EPI\_ISL\_700654); SARS-CoV-2 B.1.351 (GISAID: EPI\_ISL\_700492); SARS-CoV-2 P.1 (GISAID: EPI\_ISL\_833137); Bat-CoV-RaTG13 (GenBank: QHR63300.2); GD Pangolin (GISAID: EPI\_ISL\_410721; 471470; 471469; 471468; 471467); GX Pangolin (GISAID: EPI\_ISL\_410543; 410542; 410541; 410540; 410539); Bat-SL-CoV ZC45 (GenBank: MG772933.1); Bat-SL-CoV ZXC21 (GenBank: MG772934.1); SARS-CoV (GenBank: Urbani AAP13442.1; Tor2 NC\_004718.3; TW1 AAP37015.1; P2 ACQ82725.1; Frankfurt1 AAP33696.1); Civet SARS-CoV SZ3 (GenBank: AY304486.1); Raccoon dog SARS-CoV SZ13 (GenBank: AY304487.1); Bat CoV WIV1 (GenBank: AGZ48828.1); Bat CoV WIV16 (GenBank: KT444582.1); Bat CoV BtKY72 (GenBank: KY352407.1); Bat CoV BGR2008 (GenBank: GU190215.1). Clades were defined according to Lu et al. (*18*).

# Statistical analysis

Statistical analyses were performed using GraphPad Prism 8 software. Significance was assigned at *P* value < 0.05, unless stated otherwise. Specific tests are indicated in the figure legends for each comparison. Analysis of TCR V $\beta$  repertoires was performed using R software version 3.5.1.

# References

- 1. R. Vita *et al.*, The Immune Epitope Database (IEDB): 2018 update. *Nucleic Acids Res* **47**, D339-D343 (2019).
- 2. A. Grifoni *et al.*, A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host Microbe* **27**, 671-680 e672 (2020).
- 3. A. Nelde *et al.*, SARS-CoV-2-derived peptides define heterologous and COVID-19induced T cell recognition. *Nat Immunol* **22**, 74-85 (2021).
- 4. A. Grifoni *et al.*, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415 (2020).
- 5. J. Braun *et al.*, SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **587**, 270-274 (2020).
- 6. A. Tarke *et al.*, Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Rep Med*, PMID: 33521695 (2021).
- 7. J. Mateus *et al.*, Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **370**, 89-94 (2020).
- 8. N. Le Bert *et al.*, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **584**, 457-462 (2020).
- 9. P. Bacher *et al.*, Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity* **53**, 1258-1271 e1255 (2020).
- 10. A. Kim, S. Sadegh-Nasseri, Determinants of immunodominance for CD4 T cells. *Curr Opin Immunol* **34**, 9-15 (2015).
- 11. A. K. Sewell, Why must T cells be cross-reactive? *Nat Rev Immunol* **12**, 669-677 (2012).
- 12. J. W. Yewdell, Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. *Immunity* **25**, 533-543 (2006).
- 13. A. Cassotta *et al.*, Deciphering and predicting CD4+ T cell immunodominance of influenza virus hemagglutinin. *J Exp Med* **217**, (2020).
- 14. N. J. Tubo *et al.*, Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection. *Cell* **153**, 785-796 (2013).
- 15. S. Becattini *et al.*, T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. *Science* **347**, 400-406 (2015).
- L. Piccoli *et al.*, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* 183, 1024-1042 e1021 (2020).
- A. J. Greaney *et al.*, Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host Microbe* 29, 44-57 e49 (2021).

- 18. R. Lu *et al.*, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* **395**, 565-574 (2020).
- 19. J. A. Jaimes, N. M. Andre, J. S. Chappie, J. K. Millet, G. R. Whittaker, Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. *J Mol Biol* **432**, 3309-3325 (2020).
- 20. M. A. Tortorici, D. Veesler, Structural insights into coronavirus entry. *Adv Virus Res* **105**, 93-116 (2019).
- 21. A. C. Walls *et al.*, Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. *Nature* **531**, 114-117 (2016).
- 22. M. D. Knierman *et al.*, The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein. *Cell Rep* **33**, 108454 (2020).
- 23. D. Pinto *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290-295 (2020).
- S. Crotty, T follicular helper cell differentiation, function, and roles in disease. *Immunity* 41, 529-542 (2014).
- 25. R. Ahmed, M. J. Bevan, S. L. Reiner, D. T. Fearon, The precursors of memory: models and controversies. *Nat Rev Immunol* **9**, 662-668 (2009).
- J. B. Huppa, M. M. Davis, The interdisciplinary science of T-cell recognition. *Adv Immunol* 119, 1-50 (2013).
- H. Spits *et al.*, Characterization of monoclonal antibodies against cell surface molecules associated with cytotoxic activity of natural and activated killer cells and cloned CTL lines. *Hybridoma* 2, 423-437 (1983).
- 28. A. J. Watson, R. DeMars, I. S. Trowbridge, F. H. Bach, Detection of a novel human class II HLA antigen. *Nature* **304**, 358-361 (1983).
- 29. M. P. Lefranc *et al.*, IMGT, the international ImMunoGeneTics information system. *Nucleic Acids Res* **37**, D1006-1012 (2009).
- 30. M. J. Vavrek, A comparison of clustering methods for biogeography with fossil datasets. *PeerJ* **4**, e1720 (2016).

# Acknowledgements

We thank all participants to the study and the personnel at the hospitals for blood collection, Greta Durini for cell isolation, Daniele Lilleri and the Tipizzazione Lab of the IRCCS San Matteo Hospital Foundation San Matteo Pavia, Italy, for HLA typing.

# Funding

The study was in part financed by the Henry Krenter Foundation, the Swiss National Science Foundation (grant n. 189331) and the EOC research funds. FS and the Institute for Research in Biomedicine are supported by the Helmut Horten Foundation.

# Author contributions


ACa and FS contributed to study concept and design. JSL, DV, FM contributed to experimental work. DJ performed cell sorting. SJ provided technical support. MF performed bioinformatics analysis. TT, AFP, MB, CG, PF, ACe contributed clinical samples. ACa, AL and FS analyzed the data and wrote the manuscript. All authors contributed to interpretation of data and critical revision of the manuscript.

# **Competing interests**

Authors declare no competing interests.


# Data and materials availability

TCR V $\beta$  sequences have been deposited in the ImmunoAccess database and an open access link will be provided in due time. All other data is available in the main text or the supplementary materials.



**Figure 1.** Robust T cell response to SARS-CoV2 Spike and Nucleoprotein in CD4<sup>+</sup> memory T cell subsets. Total CD4<sup>+</sup> memory T cells from 7 COVID-19 recovered patients and 6 unexposed (pre-COVID-19) healthy donors (HD) or CD4<sup>+</sup> Tcm, Tem and cTfh cells from 7 COVID-19 recovered patients were labelled with CFSE and cultured with autologous monocytes in the presence or absence of recombinant SARS-CoV-2 Spike or Nucleoprotein. (**A**) CFSE profiles on day 7 and percentage of CFSE<sup>10</sup> proliferating Tcm, Tem and cTfh cells in a representative patient. Negative controls of T cells cultured with monocytes in the absence of antigen are reported as dashed lines. (**B**) Individual values, median and quartile values of percentage of CFSE<sup>10</sup>CD25<sup>+</sup>ICOS<sup>+</sup> cells in total CD4<sup>+</sup> memory and CD4<sup>+</sup> Tcm, Tem and cTfh memory subsets in the patients and healthy donors analyzed. Shown are also IFN-γ concentrations in the day 7 culture supernatants of SARS-CoV-2 Spike- or Nucleoprotein-stimulated memory T cell subsets. \*\*\*\*, *P* value < 0.0001 \*\*\*, *P* value < 0.001 \*\*, *P* value < 0.01 as determined by two-tailed unpaired *t* test (total CD4<sup>+</sup> memory and IFN-γ) or by two-tailed paired *t* test (CD4<sup>+</sup> Tcm, Tem and cTfh). (**C**) Pairwise comparison of TCR Vβ clonotype frequency distribution in samples of T cells

isolated from Spike-stimulated Tcm, Tem or cTfh subsets (initial input cells,  $5x10^{5}$ /subset) from patient P33. Frequencies are shown as percentage of productive templates. Total number of clonotypes is indicated in the *x* and *y* axis. Values in the upper right corner represent the number of clonotypes shared between two samples. The Venn diagrams show the number of unique and shared Spike- or Nucleoprotein-reactive clonotypes between Tcm, Tem and cTfh subsets of patient P33. The red area represents clonotypes identified in all 3 subsets. (**D**) Bar histograms showing the Chao-Jaccard overlap between pairs of TCR V $\beta$  repertoires in patients P28, P31 and P33. bioRxiv preprint doi: https://doi.org/10.1101/2021.03.23.436642; this version posted March 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.



**Figure 2.**  $CD4^+$  T cell clones target multiple sites on the Spike protein. (**A**, **B**)  $CD4^+$  T cell clones (n = 2,943) were isolated from Spike-reactive cultures of 34 COVID-19 recovered patients and their specificity was mapped by stimulation with autologous B cells and 3 pools of peptides spanning S1 $\Delta$ RBD, RBD, and S2, using as readout <sup>3</sup>H-thymidine incorporation. (**A**)

Characterization of representative T cell clones (n = 72) from patient P20. Proliferation was assessed on day 3 after a 16-h pulse with <sup>3</sup>H-thymidine and expressed as counts per minute after subtraction of the unstimulated control value ( $\Delta cpm$ ). (B) Percentage of T cell clones specific for S1ARBD (white), RBD (black), and S2 (grey) in the 34 patients tested; the number of clones tested is indicated for each patient. The distribution of all Spike-reactive T cell clones isolated from 34 COVID-19 patients (ALL, n = 2.943) is also indicated. (C) RBD-specific T cell clones (n = 1.149) isolated from 30 patients were further characterized for their epitope specificity using 15mer peptides overlapping by 10 spanning the S316-545 RBD sequence. The 20mer specificity of each clone is represented by a horizontal line and the total number of clones mapped for each patient is indicated on the right. (D) Percentage of clones specific and percentage of donors carrying T cells specific for different 20mer segments of the RBD. Data for the immunodominant region S346-365 is indicated in red. (E) Multiple sequence alignment of the immunodominant region S346-365 of SARS-CoV-2 with homologous sequences in different Sarbecoviruses, Human and animal SARSrelated coronaviruses are arranged by clades. Amino acid numbers of SARS-CoV-2 Spike protein are reported on top. Amino acid substitutions compared to SARS-CoV-2 Wuhan-Hu-1/2019 reference strain are reported; dots indicate identity to SARS-CoV-2 reference strain.






Figure 3. The immunodominant S346-365 RBD region contains nested peptides targeted by T cells restricted by HLA-DR and HLA-DP. (A, B) Rearranged TCR VB sequences of S346-365reactive CD4<sup>+</sup> T cell clones (n = 323) isolated from 23 patients were determined by RT-PCR followed by Sanger sequencing. (A) TCR Vβ gene usage in the 200 unique clonotypes identified from S346-365-reactive T cell clones. Each slice of the chart indicates a different VB gene. The size of each slice is proportional to the number of unique TCR VB clonotypes using that particular V $\beta$  gene. Color-coded legend is reported for the top 21 V $\beta$  genes (used by at least 4 different TCR Vβ clonotypes). (B) Number of S346-365-reactive T cell clones and clonotypes identified in the 23 patients. Each slice of the chart indicates a different TCR Vβ clonotype. The size of each slice is proportional to the number of sister clones bearing the same TCR V $\beta$  sequence. The number of clones analyzed from each patient is reported on top of each pie chart; the number of TCR VB clonotypes identified is reported at the center. (C) Frequency distribution of TCR Vβ clonotypes from CD4<sup>+</sup> Tcm Tem and cTfh subsets sequenced directly after ex vivo isolation from patients P31 and P33. Colored circles mark the TCR VB clonotypes found among the S346-365-specific T cell clones isolated from the same patient. Dotted lines in the graphs indicate the frequency threshold of the top 5% expanded clonotypes. (D) HLA class II isotype restriction of S346-365specific T cell clones (n = 10) isolated from P33 was determined by stimulation with peptidepulsed autologous APCs in the absence (control) or in the presence of blocking antibodies to HLA-DR, -DP, -DQ or pan HLA class II. Proliferation was assessed on day 3 after a 16-h pulse with <sup>3</sup>Hthymidine. Data are expressed as percentage of control counts per minute (Cpm). (E) Distribution of HLA class II isotype restrictions of S346-365-reactive CD4<sup>+</sup> T cell clones (n = 286) isolated from 22 patients, as determined by >80% inhibition of proliferation. (F) The minimal peptide recognized by S346-365-reactive CD4<sup>+</sup> T cell clones (n = 12) isolated from 4 patients was mapped by stimulation with autologous APCs pulsed with a panel of truncated peptides. Proliferation was assessed on day 3 after a 16-h pulse with <sup>3</sup>H-thymidine and expressed as counts per minute (Cpm). The minimal amino acid sequences recognized by T cell clones are highlighted with colored shading.



**Figure 4.** Identification of cross-reactive T cell clones by heterologous stimulations with Spike antigens. (**A**) CFSE-labelled CD4<sup>+</sup> memory T cells were stimulated with recombinant SARS-CoV-2 Spike protein in the presence of autologous monocytes. CFSE<sup>lo</sup> cells were expanded with IL-2 for 10 days, re-labelled and re-stimulated with SARS-CoV or HCoV-HKU1 Spike protein. Negative controls of T cells cultured with monocytes in the absence of antigen are reported as dashed lines. Shown are experiments performed with samples from patient P28 and P33. (**B**)

Proliferative response of representative T cell clones isolated from P28 and P33 to autologous APCs pulsed with titrated doses of recombinant Spike proteins from SARS-CoV-2 (black), SARS-CoV (grey) or HCoV-HKU1 (white). (C) Proliferative response of memory CD4<sup>+</sup> T cells isolated from P34 two years before and 1.5 months after COVID-19. CFSE-labelled cells were stimulated as above with different recombinant Spike proteins. (**D**) Proliferative response of patient P34 T cell clones isolated from the post-COVID-19 CFSE<sup>lo</sup> fractions shown above. The T cell clones were stimulated with autologous APCs pulsed with a pool of peptides spanning the entire SARS-CoV-2 Spike protein. Pie charts show the total number of clones tested and the fraction of responsive clones. (**E**) Reactivity of T cell clones isolated from each culture (in **D**) was mapped by stimulation with autologous APCs pulsed with pools of peptides spanning the S1 $\Delta$ RBD (white), RBD (black), and S2 (grey) regions of SARS-CoV-2 Spike. The histograms show the percentage of clones specific for each region. Total number of clones tested is indicated on top.



**Fig. S1.** Sorting of T cell subsets and identification of SARS-CoV-2 Spike- and Nucleoproteinreactive CD4<sup>+</sup> T cells in COVID-19 and pre-pandemic samples. (**A**) Sorting strategy to isolate CD4<sup>+</sup> total memory T cells and Tcm, Tem and cTfh subsets. (**B**, **C**) Characterization of antigenspecific T cells by CFSE dilution combined with CD25 and ICOS co-expression at day 7 following stimulation with Spike or Nucleoprotein in the presence of autologous monocytes. Negative controls of T cells cultured with monocytes alone are reported as dashed lines. Shown are data from patient P2 and from a pre-pandemic healthy donor sample (HD1).






Fig. S2. Repertoire analysis of SARS-CoV-2 Spike- and Nucleoprotein-specific T cells isolated from memory CD4<sup>+</sup> T cell subsets. (A, C) Pairwise comparison of TCR V $\beta$  clonotype frequency distribution of Spike- or Nucleoprotein-specific Tcm, Tem and cTfh cells from patient P28 (A) and P31 (C). Frequencies are shown as percentage of productive templates. Total number of clonotypes is indicated in the *x* and *y* axis. Values in the upper right corner represent the number of clonotypes shared between two samples. (B, D) Venn diagram showing the number of unique and shared Spike- or Nucleoprotein-reactive clonotypes between Tcm, Tem and cTfh subsets of patient P28 (B) and P31 (D). The red area represents clonotypes identified in all 3 subsets.

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.23.436642; this version posted March 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.



**Fig. S3.** Epitope mapping of SARS-CoV-2 Spike specific T cell clones isolated from memory T cell subsets. (**A**) T cell clones were isolated from Spike-reactive cultures of Tcm, Tem and cTfh cells as in Fig. 2 and their specificity was mapped using autologous APCs pulsed with pools of peptides spanning the S1 $\Delta$ RBD (white), RBD (black), and S2 (grey) regions of SARS-CoV-2 Spike. (**B**) RBD-specific T cell clones were further stimulated using a matrix of 15mer peptides overlapping of 10. Each line represents the specificity of a clone mapped to a 20 amino acid region. The colors indicate the subset of origin of each clone; the number of clones analyzed for each patient is indicated on the right.



**Fig. S4.** Repertoire analysis of cross-reactive CD4<sup>+</sup> T cells. (**A**, **B**) Dot plots show for patient P28 (**A**) and P33 (**B**) the shared TCR V $\beta$  clonotypes between sorted CFSE<sup>10</sup> T cells isolated following primary stimulation with SARS-CoV-2 Spike protein and sorted CFSE<sup>10</sup> T cells isolated following secondary re-stimulation with SARS-CoV or HCo-HKU1 Spike proteins. Frequencies are shown as percentage of productive templates. Total number of clonotypes is indicated in the *x* and *y* axis. Values in the upper right corner represent the number of clonotypes shared between two samples. The Venn diagrams show the number of clonotypes shared among different Spike-reactive cultures.

Age (years)	24 – 76 (median = 43)			
Gender				
Male	76% (26/34)			
Female	24% (8/34)			
Illness <sup>1</sup>				
Asymptomatic	3% (1/34)			
Mild	53% (18/34)			
Moderate	23% (8/34)			
Severe	21% (7/34)			
Hospitalization status				
Never	79% (27/34)			
Hospitalized	21% (7/34)			
SARS-CoV-2 PCR test				
Positive	94% (32/34)			
Negative	3% (1/34)			
Not performed	3% (1/34)			
Sample collection date	June – November 2020			
SARS-CoV-2 Serology <sup>2</sup>				
lgG (RU)	0.658 – 6.422 (median = 6.422)			
IgM (RU)	0.100 – 2.441 (median = 0.714)			
IgĂ (RU)	0.100 – 4.553 (median = 0.649)			
Days post symptom onset or positive PCR test	43 – 164 (median = 85)			

# **Table S1.** Characteristics of study participants (n = 34)

(1) According to the guideline in <u>https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</u>

(2) Titres of SARS-CoV-2 RBD antibodies expressed as Relative Units (RU) of serum IgG, IgM and IgA. Cut-off value = 0.500

Patient	Clonotype ID	V-gene and allele	J-gene and allele	D-gene and allele	CDR3 junction (aa)	Sister clones (n)	MHC restrictio
P1 P1	P1-1 P1-2	TRBV7-8101 TRBV18101	TRBD1*01 NA	TRBJ2-5*01 NA	CASGASLGTQYF NA	1	NA HLA-DR
P1 P2	P1-2 P2-1 P2-2	TRBV4-1'01 or TRBV4-1'02 TRBV20-1'01 or TRBV20-1'02	TRBJ2-5101 TRBJ2-1101	TRBD2*01 TRBD1*01	CASSODDLAGVTQYF CSARDRVQGLQFF	5	HLA-DR HLA-DR
P2 P2	P2-3	TRBV11-3*01 or TRBV11-3*02 or TRBV11-3*03 or TRBV11-3*04	TRBJ2-5*01	TRBD2*01	CASSODDLAGVTQYF	2	HLA-DR
P2 P2	P2-4 P2-5	TRBV30*01 or TRBV30*02 TRBV7-3*01 or TRBV7-3*02 ORF or TRBV7-3*04	TRBJ2-5*01 TRBJ2-5*01	ND TRBD2*01	CASSQDDLAGVTQYF CASSQDDLAGVTQYF	2	HLA-DR HLA-DR
P2 P3	P2-6 P3-1	TRBV10-2*01 or TRBV10-2*01 TRBV5-8*01	NA TRBJ2-3*01	NA TRBD2*01	NA CASSSTSATDTQYF	1 9	NA HLA-DR
P3 P3	P3-2 P3-3	TRBV28*01 TRBV9*01	TRBJ2-7*01 TRBJ1-3*01	TRBD2*02 TRBD1*01	CASSFNGRSGLNEQYF CASSPLPGGSGNTIYF	3	HLA-DR HLA-DR
P3 P3	P3-4 P3-5		TR8.J2-2*01 TR8.J1-2*01	TRBD2*01 ND	CASSFGSDTGELFF ND	2	HLA-DR HLA-DR
P3 P3	P3-8 P3-7	TREV2-101 TREV20-1102 TREV20-1101 or TREV20-1102 TREV25-101 or TREV25-101 TREV25-101 TREV25-101 TREV25-101 TREV25-101	TRBJ1-2*01 NA	TRBD1*01 NA	CSARDGTGIRGYGYTF NA	1	HLA-DR HLA-DR
P3 P3	P3-8	TRBV25-1101	TRBJ2-6*01 TRBJ2-1*01	ND TRBD1*01			HLA-DR HLA-DR
P3	P3-0 P3-10 P6-1 P6-2 P6-3	TR8V28-01 TR8V7-6*01	NA	NA	CASSECTION CASES C	1	
P6 P6	P6-1 P6-2		NA TRBJ1-6*02 TRBJ1-4*01 TRBJ1-1*01	NA TRBD2*01 TRBD1*01 TRBD1*01	CASSLGLDNSPLHF CSVMAGGEKLFF	1	HLA-DP HLA-DP HLA-DP
P6 P6	P6-3 P6-4	TRBV29-1101 TRBV19101	TRBJ1-1*01 TRBJ1-1*01	TRBD1*01 TRBD1*01		1	HLA-DP HLA-DP
P6 P6	P8-5 P8-6	TRBV12-3*01 or TRBV12-4*01 or TRBV12-4*02 TRBV19*01	NA TRB.11.5101	NA NA	NA.	1	HLA-DQ HLA-DR
P7	P64 P65 P7-1 P7-2 P8-1 P8-2 P8-3 P9-1 P9-2 P9-3 P9-4 P9-5 P9-6 P9-7 P9-8 P9-7 P9-8 P9-9 P9-7 P9-8 P9-9 P9-8 P9-9 P9-8 P9-8 P9-8 P9-8	Weinschaft 1 W	1782.11-301 1782.11-301 1782.11-301 1782.11-301 1782.11-301 1782.12-301 1782.22-90 CoFe or 1782.23-91 1782.24-901	TRBD1*01	CASSSUAPINITKOPP NA CSARDNRANTEAFF CATSGOTGGLSNOPOHF CASSDNRKNEKLFF NA CATSDLSRSETOYF	3	HLADP HLADR HLADR HLADR HLADR HLADR HLADR HLADR HLADR
P8	P8-1	TRBV12-3101 TRBV12-3101	TRBJ1-4*01	TRBD1*01	CASSDNRKNEKLFF	3	HLA-DR
P8 P8	P8-2 P8-3	TRBV24-1101 or TRBV24-1102 TRBV24-1101 or TRBV24-1102	TRBJ2-2P*01 CRF or TRBJ2-3*01 TRBJ2-5*01	NA TRBD1*01	CATSDLSRSETQYF	2	HLA-DR HLA-DR
P9 P9	P9-1 P9-2	TRBV7-9*01 or TRBV7-9*02 or TRBV7-9*03 TRBV4-1*01 or TRBV4-1*02	TRBJ1-5*01 TRBJ1-5*01	TRBD1*01 TRBD2*02	CASSWEGSSNQPQHF CASSQEGPWRSGNQPQHF	3 2	
P9 P9	P9-3 P9-4	TRBV11-2101 TRBV12-4101	TRBJ1-4*01 TRBJ2-1*01	TRBD1*01 TRBD2*01	CATSULSISETUTF CASSWEGSSNOPOHF CASSQEOPWRSONOPOHF CASSQTGTNEKLFF CASSQLAMINEQFF CASSQDHPKGEAFF		HLA-DR NA
P9 P9	P9-5 P9-6	TRBV14*02 TBBV14*02	TRBJ1-1*01 TRB (2,7501	TRBD1*01 TRBD1*01	CASSODHPKGEAFF CASSOVPARTYFOYF	1	NA HLA-DR HLA-DR HLA-DR
P9	P9-7	11890-1192 11897-1213 - 11897-1234 11897-1213 - 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-1234 11897-134	TRBJ2-7*01	TRBD2*01	CASSPRRLAGNYEQYF	1	HLA-DR
P2 P2	P9-0	TREV7-2 01 OF TREV7-2 02 OF TREV7-2 03 OF TREV7-2 04 TREV7-7 01	TRBJ1-4*01	TRBD2*01	NA CASSLDTGEKLFF CASSLVTGNTGELFF		NA
P2 P2	P9-10 P9-11 P10-1	TRBV7-0101 TRBV7-0101 or TRBV7-020 or TRBV7-003	TR8J2-5*01 TR8J2-5*01	TRBD1*01	CASSLVTGNTGELFF CASSLEVTLVETQYF		NA HLA-DR HLA-DR
P10 P11	P11-1	TRBV20-1*01 or TRBV20-1*02 TRBV7-9*01 or TRBV7-9*02 or TRBV7-9*03	TRBJ1-4*01 TRBJ1-5*01	TRBD1*01 TRBD1*01	CSARDLSTGEDEKLFF CASSLEGNQPQHF	2	
P11 P11	P11-2 P11-3	TRBV6-5101 TRBV9101	TR8J2-1*01 TR8J2-2*01	TRBD2*02 TRBD2*01	CASSYSGDLAGVREQFF CASSVALRGLAGELFF		HLA-DR HLA-DR HLA-DR
P12 P12	P12-1 P12-2	TR8V7-8101	TR8J2-7*01 TR8 I1 2*01	TR8D2*01	CASSPSGAGQYF	4	
P13 P13	P13-1 P13-2	TRBV7-7*01	NA TRBD1*01	TRBJ2-1*01	CASSLDLGNEQFF	1	HLA-DR HLA-DR HLA-DR
P13	D12.2	TRBV11-3 TRBV1-3 TRBV7-9 TRBV7-901 or TRBV7-9r03 TRBV27-91 TRBV27-91	TRBD1*01 TRBD2*02	TRBJ1-8*02 TRBJ2-5*01	CASSLDQGSPLHF		HLA-DR HLA-DR
P13 P14	P13-4 P14-1 P17-1	TRBV7-0*01 or TRBV7-0*02 or TRBV7-0*03 TRBV27*01	TR8D2*02 TR8D1*01	TRBJ1-5*01 TRBJ1-5*01	CASSREGGOPOHF CASSFLGNNQPOHF	1	NA NA
P17 P17	P17-2	TR8V5-1101 TR8V5-6101	TR8.J2-7*01 TR8.J1-2*01	NA TRBD2*01	CASSLGGYEQYF CASSSGGVNYGYTF		HLA-DR HLA-DR HLA-DR
P18 P18	P18-1	TRBV30*01 TDB/4011	TR8J2-7*01	TR8D2*02	CAWSLAGAFVQYF	5	HLA-DR
P18 P18 P18	P18-2 P18-3 P18-4 P18-5 P18-6 P18-6 P18-7	TRBV6-511	TRBJ1-2*01	TRBD1*01	CASSYSNOGASGGYTF	3	NA HLA-DR HLA-DR
P18	P18-5	1989/3-8701 TRBV3-1701	TRBJ2-1101	TRBD1*01	CASSQDPREQFF		NA
P18 P18	P18-6 P18-7	TR8V6-4101 TR8V15102	TRBJ2-3*01 TRBJ2-7*01	TRBD2*01 TRBD1*01	CASSDFGSADTOYF CATSSMDRGGTYEOYF		HLA-DR NA
P21 P21	P21-1 P21-2	TRBV12-4101 TRBV6-5101	NA TRBJ1-6*02 TRBJ2-7*01	NA TRBD1*01	NA CASRRDRGGSSPLHF	8	NA HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR
P21 P21	P21-3 P21-4	TRBV14*01 TRBV3-1*01	TRBJ2-7*01 TRBJ1-5*01	ND TRBD2*01	CASSODPSLEDYF CASSODLPGSNOPOHF	2	HLA-DR HLA-DP
P21	P21-5	TRBV6-5*01 TRBV6-5*01	TRBJ1-3*01 TRB.H. 5*04	TRBD1*01	CATQQGFSSGNTIYF	2	HLA-DR
P21	P21-5	18978-3701 TR8910-3701 R8910-3702 or TR8910-3704 TR8910-3702 or TR8914-02 TR8912-1701 or TR8912-1702 TR89120-1702 TR89120-1702	TRBJ2-3*01	NA TRBD1*01	NA CAISDGDRTTDTQYF		
P21 P21	P21-8 P21-9	TRBV14*01 or TRBV14*02 TRBV20-1*01 or TRBV20-1*02	NA TR8.12-101 TR8.11-501 TR8.11-401 TR8.11-401	NA TRBD1*01	NA CSARGEVEGFSYNEHFS CATSGGLNNQPQHF	1	NA HLA-DR
P21 P21	P21-10 P21-11	TRBV24-1101 TRBV28101	TRBJ1-5*01 TRBJ1-4*01	TRBD2*02 TRBD2*01		1	HLA-DR HLA-DR
P21 P21	P21-12 P21-13	TRBV30101 TRBV6-5101	TRBJ1-6*02 TRBJ1-6*01 or TRBJ1-6*0?	TRBD1*01 NA	CASKPDRGLINKSPLHF NA CASKPDRGGNYGYTF CSALRTEKPETQYF CSAHSGRGTSTDTQYF CASKAGTGGPYEQYF	1	HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DP
P21 P22	P21-14 P22-1	TRBV8-5101 TRBV2-0.1101	TRBJ1-6*01 or TRBJ1-6*02 TRBJ1-2*01 TRBJ2-5*01	TRBD1*01 TRBD1*01	CASKPDRGGNYGYTF CSALRTEKPETOVE	1	HLA-DR HLA-DR
P23	P23-1	TRBV20-1101 TRB0-01-101	TR8D2*01	TRBJ2-3*01	CSAHSGRGTSTDTOYF	1	NA
P25	P25-1	1768/05/01 1768/25/01 1768/25/01 1768/2701 1768/2701 1768/2701 1768/1701 1768/1701 1768/1701	TRBJ2-1101	TRBD1*01	CASSSLGQGGEOFF	9	NA HLA-DR HLA-DR HLA-DR HLA-DR
P25 P25	P25-2 P25-3	TRBV11-2701 TRBV12-3701	TRBJ2-3*01 TRBJ1-2*01	TRBD1*01	CASSLADSITIDTQYF		HLA-DR HLA-DR
P25 P25	P25-4 P25-5	TRBV2'01 TRBV2'01 TRBV2'01 or TRBV2'02 or TRBV2'03 TRBV30'01 TRBV7.7'01	TRBJ2-5*01 NA	TRBD2*01 NA	CASSESAGGTPRGTQYF NA	1	HLA-DR NA
P25 P25	P25-8 P25-7	TRBV30*01 T9BV7.7*01	NA TRBJ2-5*01	NA TRBD2*01	NA CASSOLGLGGGGTQYF	1	NA HI A DR
P29	P29-1	TR8V7-7*01	TR8J2-6*01	TRBD1*01	CASSPGTGGSGANVLTF CAWSVKDSNTEAFF CASSLAIPGLAGYSNOPQHF	4	HLA-DR HLA-DR HLA-DR HLA-DR
P30	P30-2	TRBV6-5101	TRBJ1-5*01	TRBD1*01	CASSLAIPGLAGYSNQPQHF	Î	HLA-DR
P30 P30	P30-3 P30-4	TRBV12-3101 TRBV7-9101	TR8J2-7*01 TR8J2-1*01	TRBD1*01	CASSINEOFF		NA HLA-DR
P30 P30	P30-5 P30-6	TRBV3-1101 TRBV25-1101	TRBJ2-2*01 TRBJ1-3*01	TRBD2*02 TRBD1*01	CASSELAGPLLPGELFF CASSESTRTSGNTIYF	1	HLA-DR HLA-DR
P30 P30	P30-7 P30-8	TRBV11-1101 TRBV12-4101	TRBJ1-2*01 TRBJ2-1*01	TRBD1*01 TRBD1*01	CASSSSGRYHNYGYTF CASSFGGKSYNEOFF		HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR HLA-DR
P30 P30	P30-9 P30-50	TRBV12-4101 TRBV0101	TRBJ2-1101 TRB I1-4101	TRBD1*01 TRBD1*01	CASSTTORSYNEOFF CASSYDPORRI NEW F		HLA-DR HLA-DR
P30	P30-11	T09/(0.6551	TRBJ1-6*01	TRBD1*01	CASSYGGNNSPLHF	1	HLADR
P30 P30	P30-12 P30-13	TRBV28101 TRBV24-1101	TR8J2-7*01 TR8J2-3*01	TRBD1*01	CATSDSQFSSTDTQYF		HLA-DR HLA-DR
P30 P30	P30-14 P30-15	1786/28/01 1786/28/01 1786/24/101 1786/26/01 1786/26/01 1786/26/01 1786/26/01 1786/26/101 1786/26/101	TRBJ1-1*01 TRBJ1-2*01	TRBD1*01 NA	CASSVEVNTEAFF CASSIDAANNYGYTF	1	HLA-DR NA
P30 P30	P30-16 P30-17	TRBV20-1104 TRBV7-8101	NA NA	NA	NA NA CASSEYRSGGSPLHF	1	HLA-DR HLA-DR
P31	P31-1	TRBUT (MO)	TRBJ1-6*01	TR8D2*02	CASSEYRSGGSPLHF	2	HLA-DR
P31	P31-3	TRBV2*01 TRBV9*01 TRBV9*01 TRBV9*02	TRBJ2-1*01	TRBD1*01	CASSPLRSGAQFF	1	HLA-DR
P31 P31	P30-17 P31-1 P31-2 P31-3 P31-4 P31-6 P31-6 P31-6 P31-7 P31-8	TRBVI102	TRBJ2-2*01 TRBJ2-2*01	TRBD2*02	CASSVESAWSGELFF	1	HLADR HLADR HLADR HLADR HLADR HLADR HLADR
P31 P31	P31-6 P31-7	TRBV20-1101 TRBV20-1101	TRBJ2-5*01 TRBJ2-7*01	TRBD1*01 TRBD1*01	CASSVRPPQTGGARETQYF CSAREGQSYEQYF ASSVVGTGGPGLAGGRTDTQ	1	HLA-DR HLA-DR HLA-DR
P31 P31	P31-8 P31-9	TRBVIn01 TRBV5-6101	TR8J2-3*01 TR8J2-1*01	TRBD2*02 TRBD2*02	CASSPGGLXVXNXQFF	1	HLA-DR HLA-DR
P31	P31-10	TRBV9102	TRBJ2-5*01 TRB 12 3*01	NA TREDITOT	CASSVDSHGTQYF	1	HLA-DR HLA-DR
P31	P31-12	TRBV20-1101	TRBJ2-3*01	TRBD2*01	CSAGLGLVTDTQYF	1	HLA-DR
P31 P31	P31-13 P31-14	TRBV25-1101	TRBJ1-3*01 NA	NA NA	CASSALGGGPGNTIYF NA	1	HLA-DR
P31 P31	P31-15 P31-16	TRBV12-4102 TRBV12-3101	NA NA	NA NA	NA. NA	1	HLA-DR HLA-DR
P32 P32	P32-1 P32-2	TR8V6-5101 TR8V5-6101	TRBD2*02 TRBD1*01	TRBJ2-7*01 TRBJ1-1*01	CASSRHPPSLAGVMYEQYF CASAEDRGLEAFF	6	HLA-DR NA
P32 P32	P31-0 P31-10 P31-11 P31-12 P31-13 P31-14 P31-14 P31-14 P31-15 P31-16 P32-1 P32-2 P32-2 P32-2 P32-3 P32-4 P32-5 P32-7	TR8V5.6101 TR8V5.6101	TR8D1*01 TR8D1*01	TRBJ2-1*01 TRBJ2-1*01	CASSYDRENEQFF	5	NA NA
P32	P32-5	TRBV19*01 TDBV14 1912	TRED1*01	TRBJ1-2*01	CASRTTGTGAFYGYTF	2	NA MA DR
P32	P32-7	TR846-501	TR8D1*01	TRBJ1-6*02	CASRPGANNSPLHF	2	HLA-DR
P32	P32-8 P32-9	1 PB V 3-1101 TRBV 5-6101	TRBD1*01	TRBJ2-2*01 TRBJ2-2*01	CASSYDRSTGELFF	2	NA-NA
P32 P32	P32-10 P32-11	TRBV12-3*01 TRBV19*01	TRSD2*01 TRSD1*01	TRBJ1-5*01 TRBJ1-2*01	CASSLALNNGGAHF CASSLQANYGYTF	2	NA HLA-DR
P32 P32	P32-12 P32-13	TRBVI001 TRBV10-3101 or TRBV10-3102 or TRBV10-3104	TRBD1*01 TRBD1*01	TRBJ2-7*01 TRBJ2-1*01	CASSAGTGGLYEOYF CAITTDRGSNEOFF	2	HLA-DR HLA-DR
P32 P32	P32-14 P32-15	TRBV3-1101 TRBV25-1101	TRBD2*02 TRBD1*01	TR8J2-7*01 TR8J1-4*01	CASSREWYEQYF CASREGGITRAFKI FF	2	NA HLAJNR
P32	P32-16	TRBV3-1101 or TRBV3-1102	NA TRR01101	NA TRB ID 6101	NA CASSI DEADTONE	2	HLA-DR
P32	P32-18	TRBV24-101 TRBV24-1101	TRED1*01	TRBJ1-5*01	CATSDGQTRNQPQHF		HLA-DR
P32	P32-19 P32-20	TRBV20101 TRBV12-4101	TRED1*01	TRBJ2-1*01	CASSFW/RDEOFF		NA
P32 P32	P32-21 P32-22	TRBV6-2*01 or TRBV6-3*01	TR8D2*01 TR8D2*01	1rd5J2-5*01 TR8J2-2*01	CASTIGGHSGGVTGELFF		HLA-DR HLA-DR
P32 P32	P32-23 P32-24	TR8V5-6101 TR8V3-1101	TRBD1*01 TRBD2*01	TRBJ1-3*01 TRBJ2-4*01	CASSFDRGNTIYF CASSQDIGGLAKNIQYF	1	NA HLA-DR
P32 P32	P32-25 P32-24	TRBV5-6101 TRBV5-6101	TRBD2*02 TRBD1*01	TRBJ2-7101 TRBJ2-2101	CASSPORGNEOYF CASTRORNTGFLFF	1	HLA-DR
P32 P32	P32-27 P32-28	TRBV28101 TRBV12-411	TR8D2*01 TR8D2*01	TRBJ1-3*01 TRBJ2-5*01	CASSPSGGFGNTIYF CASSLAGARVFTOVF		HLA-DR HLA-DR
P32	P32-29	TR8V7-611	TRBD2*02	TR8J2-7*01	CASSLAQGSRVAGSYEQYF		HLA-DR
P32	P32-30 P32-31	176594-2701 TR897-3701	TRBD1*01	TRBJ2-6*01	CASSQLASTASNOPOHF CASSLGTGLSGANVLTF		HLA-DR
P32 P32	P32-32 P32-33	TRBV6-6*01 or TRBV6-6*03 TRBV18*01	TRBD2*01	TREJ2-7*01	CASSPTNYEQYF		HLA-DR NA
P32 P32	P32-34 P32-35	TRBV12-3101 TRBV12-3101	TRBD2*01 TRBD2*01	TRBJ2-2*01 TRBJ2-2*01	CASSFGGGXXGXLFF CASSFGGGLTGELFF		NA NA
P32 P32	P32-38 P32-37	TRBV7-0*01 or TRBV7-0*03	TRBD2*01 TRBD2*01	TRBJ2-2*01 TRBJ2-1*01	CASSLGTSMGNTGELFF CASSQRTR00NF0FF	1	NA HLA-DR NA
P32	P32-38		TRBD1*01	TRBJ2-3*01	CASSLGTHSTDTOYF		NA
P32	P32-39	TRBV5-6101 TRBV7-2102 or TRBV7-2103 TRBV5-6101 TRBV5-6101	TRED1*01	TRBJ2-1*01	CASSLVGRQGGNEQFF		NA HLA-DR HLA-DR
P32	P32-41 P32-42	TR8V24-1101	TRBD1*01 TRBD1*01	1r05JZ-7*01 TR8J2-3*01	CASSRDRONEQYF		HI ALDR
P32 P32	P32-43 P32-44	TR8V5-6101 TR8V18101	NA NA	NA NA	NA NA	1	NA HLA-DR HLA-DR HLA-DP NA
P33 P33	P33-1 P33-2	TRBV12-4101 TRBV6-6101	TRBJ2-7*01 TRBJ2-1*01	TRBD2*01 TRBD1*01	CASSSPAGLAGSSYEQYF CASSYSGVRSADEOFF	5	HLA-DR HLA-DP
P33 P33	P33-3 P33-4	TRBV8-2101 TRBV8-4101	TR8J2-1101 TR8J1-1101 TR8J2-3101	TRBD1*01 TRBD1*01	CASSSPTDRRNTEAFF	2	NA HLA-DP
P33	P33-5	TRBV24-1102 TRBV24-1102	TR8J2-2*01	TRBD2*01	CATSSTRNTGELFF	2	NA
P33	P33-6	TRBVP01	TRBJ1-2*01	TRBD2*01	CASSVEPNEQFF CASRVGPPGVGGSTF	2	HLA-DR
P33 P33	P33-8 P33-9	THBV29-1103 TRBV8-6102	1NSJ2-5*01 TRBJ2-7*01	TRBD1*01	CASMGTATYEQYF	2	HLA-DP HLA-DP
P33 P33	P33-10 P33-11	TRBV6-2101 TRBV6-6102	TRBJ1-6*02 TRBJ1-4*01	TRBD2*02 TRBD1*01	CASSYGGRGGNSPLHF CASSYPGAANEKLFF		HLA-DP HLA-DP
P33	P33-12	TRBV8-6102	TRBJ1-2*01 TRB.H 2904	TRBD1101	CASTSLDTEGYTF		HLA-DP
P33	P33-13	TRBV6-01	TRBJ1-2*01	TRBD1*01	CASSSFGQGAHRHGYTF		HLA-DP
P33 P33	P33-15 P33-16	TR8V6-6102 TR8V18101	TRBJ1-4*01 TRBJ2-7*01	1RBD1*01 TRBD1*01	CASSYSTGPVGTNEKLFF CASSPVTGGISTYEOYF		HLA-DP HLA-DP
P33 P33	P33-17 P33-18	TRBV24-1102 TRBV12-3101	TRBJ1-4*01 TRBJ2-4*01	TRBD1*01 TRBD2*01	CATSGAGTSDEKLFF CASSLGGIAKNIQYF		HLA-DP HLA-DR
P33	P33-19 P33-20	TRBV27*01 T9RV3.1*01	TRBJ2-1101 TRB (1.4101	TRBD2*02 TRBD1*04	CASSPSSGRGYNEQFF CASSPORI DAVIDAL LAC		HLA-DP HLA-DP
P33	P33-20	TRBV3-1101 TRBV3-1101	TRBJ1-0101	TRBD1*01	CASSODOPOLRTEAFF		HLA-DP HLA-DR
P33 P33	P33-22 P33-23	TRBV9101 TRBV24-1101	1N5J2-7*01 TRBJ2-2*01	TRBD1*01	CASSAGTGGSTSSIF CATSDPRDRSVTGELFF	1	HLA-DR HLA-DP
P33 P33	P33-24 P33-25	TRBV9101 TRBV2101	TRBJ2-7*01 TRBJ2-3*01	ND TRBD1*01	CASSAGTGGFYEQYL CASSEALGRVTDTQYF		HLA-DR HLA-DP
	P33-26 P33-27	TRBV3-1101 TRBV24-1101	TRBJ2-2*01 TRBJ1-4*01	TRBD1*01 TRBD1*01	CASSPPGTGRNTGELFF CATSGTNNNEKLFF		HLA-DR HLA-DP
P33 P33	P33-28	TR8V8-6102 T98V7-2441	TRBJ2-1101	TRBD1*01	CASRDRENEQFF		HLA-DP
P33 P33 P33	P33-29	1980-7-2701 TRBV6-6102	TRBJ1-1'01	TRBD1*01	CASTSRTGLTEAFF		HLA-DP
P33 P33 P33 P33 P33 P33	P33-30	TMSV6-2101	TR8J2-3*01 TR8J2-2*01	TRBD1*01 TRBD1*01	CASSYLDLPQSDTQYF CASSYGGRGPTGELFF		HLA-DP HLA-DP
P33 P33 P33 P33 P33 P33 P33 P33	P33-30 P33-31 P33-32	INDV0-2101				1 1	
P33 P33 P33 P33 P33 P33 P33 P33 P33 P33	P33-30 P33-31 P33-32 P33-33 P33-34	TRBV0-2-01 TRBV0-01 TRBV18*01	TR8J1-2*01 TR8J2-3*01	TRBD2*01 TRBD1*01	CASSPGXAXSDXQYF		HLA-DP
P33 P33 P33 P33 P33 P33 P33 P33 P33 P33	P33-30 P33-31 P33-32 P33-33 P33-34 P33-35 P33-36	TRBV0-01 TRBV0-01 TRBV1-01 TRBV1-201 TRBV1-201	TRBJ1-2*01 TRBJ2-3*01 TRBJ1-4*01 NA	TRBD2*01 TRBD1*01 TRBD2*01 NA	CASSPGXAXSDXQYF CASSFLGGAANEKLFF NA	1	NA       NAA       HAAG       HAAG

**Table S2.** TCR V $\beta$  sequence and MHC restriction of S346-365 specific T cell clones.

T cell clones				T cell clone specificity (Cpm)			T cell clone TCR Vβ sequence			
Clone ID	1st stimulation	2nd stimulation	No Ag	SARS-CoV-2	SARS-CoV	HKU1	V-gene and allele	J-gene and allele	D-gene and allele	CDR3 junction (aa)
P28-SARS1-2	SARS-CoV-2	SARS-CoV	106	1459	2495	285	TRBV24-1*01	TRBJ1-5*01	TRBD1*01	CATSDGARGRQPQHF
P28-SARS1-28	SARS-CoV-2	SARS-CoV	186	2410	2262	373	TRBV18*01	TRBJ2-5*01	TRBD1*01	CASSPPGQGEETQYF
P28-SARS1-29	SARS-CoV-2	SARS-CoV	307	4190	2293	903	TRBV7-2*01	TRBJ2-3*01	TRBD2*01	CASSLERTDTQYF
P28-SARS1-55	SARS-CoV-2	SARS-CoV	229	12923	8307	697	TRBV7-3*01	TRBJ2-3*01	TRBD1*01	CASSTDREDTQYF
P28-HKU1-13	SARS-CoV-2	HKU1	115	3822	3995	4220	TRBV18*01	TRBJ1-2*01	TRBD2*01	CASSPPSRNRDGYTF
P33-SARS1-8	SARS-CoV-2	SARS-CoV	285	2829	2771	435	TRBV10-3*03	TRBJ1-3*01	TRBD1*01	CAIRRDIASGNTIYF
P33-SARS1-18	SARS-CoV-2	SARS-CoV	227	10714	9371	615	TRBV10-3*03	TRBJ1-3*01	TRBD1*01	CAIRRDIASGNTIYF
P33-SARS1-41	SARS-CoV-2	SARS-CoV	336	2281	4795	ND	TRBV10-3*01	TRBJ1-3*01	TRBD1*01	CAIRRDIASGNTIYF
P33-SARS1-43	SARS-CoV-2	SARS-CoV	268	12315	11410	ND	TRBV10-3*02	TRBJ1-3*01	TRBD1*01	CAIRRDIASGNTIYF
P33-SARS1-13	SARS-CoV-2	SARS-CoV	290	7485	10091	154	TRBV30*01	TRBJ1-1*01	TRBD1*01	CAWSVPPGGYTEAFF
P33-SARS1-15	SARS-CoV-2	SARS-CoV	253	17349	18702	ND	TRBV30*01	TRBJ1-1*01	TRBD1*01	CAWSVPPGGYTEAFF
P33-SARS1-42	SARS-CoV-2	SARS-CoV	270	8834	7148	ND	TRBV30*01	TRBJ1-1*01	TRBD1*01	CAWSVPPGGYTEAFF
P28-SARS1-23	SARS-CoV-2	SARS-CoV	253	7038	7612	360	TRBV20-1*04	TRBJ1-2*01	TRBD2*02	CSARGEGNYGYTF
P33-SARS1-30	SARS-CoV-2	SARS-CoV	239	7228	6901	ND	TRBV20-1*01	TRBJ1-2*01	TRBD1*01	CSARGEGNYGYTF
P33-SARS1-49	SARS-CoV-2	SARS-CoV	185	3699	4164	3256	TRBV10-3*01	TRBJ1-2*01	TRBD1*01	CAISDWTDYGYTF
P33-SARS1-51	SARS-CoV-2	SARS-CoV	416	7271	9738	262	TRBV27*01	TRBJ2-3*01	TRBD2*01	CASSFFPPSGTDTQYF
P33-SARS1-19	SARS-CoV-2	SARS-CoV	253	3225	5254	ND	NA	NA	NA	NA
P33-SARS1-50	SARS-CoV-2	SARS-CoV	170	20289	19721	ND	NA	NA	NA	NA
P33-SARS1-55	SARS-CoV-2	SARS-CoV	273	4059	3068	ND	TRBV18*01	NA	NA	NA
P33-HKU1-2	SARS-CoV-2	HKU1	331	5894	4763	5828	TRBV10-3*01	TRBJ1-2*01	TRBD1*01	CAISDWTDYGYTF
P33-HKU1-17	SARS-CoV-2	HKU1	231	4767	2016	4847	TRBV7-2*01	TRBJ2-3*01	TRBD1*01	CASSGNRASTDTQYF
P33-HKU1-1	SARS-CoV-2	HKU1	520	19450	ND	5105	TRBV18*01	NA	NA	NA
P33-HKU1-8	SARS-CoV-2	HKU1	279	8517	ND	4911	NA	NA	NA	NA
P33-HKU1-15	SARS-CoV-2	HKU1	295	9337	ND	8885	NA	NA	NA	NA
P33-HKU1-18	SARS-CoV-2	HKU1	270	7213	ND	7157	NA	NA	NA	NA
P33-HKU1-59	SARS-CoV-2	HKU1	416	15270	ND	7314	NA	NA	NA	NA

**Table S3.** Specificity and TCR V $\beta$  sequence of cross-reactive T cell clones.

Shading colors identify sister T cell clones (same clonotype) ND, not done NA, not available